A stable prostacyclin analogue reduces high serum TNF-α levels in diabetic patients

Experimental and Clinical Endocrinology and Diabetes

Volumn 112, Issue 7, 2004, Pages 390-394

  Fujiwara, K ^a   Nagasaka, A ^a   Nagata, M ^a   Yamamoto, K ^a   Imamura, S ^a   Oda, N ^a   Sawai, Y ^a   Hayakawa, N ^a   Suzuki, A ^a   Itoh, Mitsuyasu ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Diabetes mellitus; Prostacyclin (prostaglandin I2); Tumor necrosis factor (TNF )

Indexed keywords

ANTIDIABETIC AGENT; BERAPROST; GLUCOSE TRANSPORTER 4; PROSTACYCLIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; HYPERGLYCEMIA; MALE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; EPOPROSTENOL; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3142745646     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-821024     Document Type: Article

References (36)

1. Amore A, Cirina P, Mitola S, Peruzzi L, Gianoglio B, Rabbone I, Sacchetti C, Cerutti F, Grillo C, Coppo R. Nonenzymatically glycated albumin (Amadori adducts) enhances nitric oxide synthase activity and gene expression in endothelial cells. Kidney Int 1997; 51: 27-35
2. Askari B, Ferreri NR. Regulation of prostacyclin synthesis by angiotensin 11 and TNF-alpha in vascular smooth muscle. Prostaglandins Other Lipid Mediat 2001; 63: 175-187
3. Benjafield AV, Glenn CL, Wang XL, Colagiuri S, Morris BJ. TNFRSF1 B in genetic predisposition to clinical neuropathy and effect on HDL cholesterol and glycosylated hemoglobin in type 2 diabetes. Diabetes Care 2001; 24: 753-757
4. Bullo M, Garcia-Lorda P, Salas-Salvado J. Plasma soluble tumor necrosis factor alpha receptors and leptin levels in normal-weight and obese women: effect of adiposity and diabetes. Eur J Endocrinol 2002; 146: 325-331
5. Coughlan MT, Oliva K, Georgiou HM, Permezel JM, Rice GE. Glucose-induced release of tumour necrosis factor-alpha from human placental and adipose tissues in gestational diabetes mellitus. Diabetic Med 2001; 18: 921-927
6. Crutchley DJ, Conanan LB, Que BG. Effects of prostacyclin analogs on the synthesis of tissue factor, tumor necrosis factor-alpha and interleukin-1 beta in human monocytic THP-1 cells. J Pharmacol Exp Therp 1994; 271: 446-451
7. Garvey WT, Maianu L, Zhu JH, Hancock JA, Golichowski AM. Multiple defects in the adipocyte glucose transport system cause cellular insulin resistance in gestational diabetes. Heterogeneity in the number and a novel abnormality in subcellular localization of GLUT4 glucose transporters. Diabetes 1993; 42: 1773-1785
8. Hart PH, Whitty GA, Piccoli DS, Hamilton JA. Control by IFN-gamma and PGE2 of TNF alpha and IL-1 production by human monocytes. Immunology 1989; 66: 376-383
9. Haynes DR, Whitehouse MW, Vernon-Roberts B. The prostaglandin E1 analogue, misoprostol, regulates inflammatory cytokines and immune functions in vitro like the natural prostaglandins E1, E2 and E3. Immunology 1992; 76: 251-257
10. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415
11. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665-668
12. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91
13. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-1278
14. Kainoh M, Maruyama I, Nishio S, Nakadate T. Enhancement by beraprost sodium, a stable analogue of prostacyclin, in thrombomodulin expression on membrane surface of cultured vascular endothelial cells via increase in cyclic AMP level. Biochem Pharmacol 1991; 41: 1135-1140
15. Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, Fujii M, Tsuchihashi K, Goto H, Nakatani K, Yano Y. Serum levels of tumor necrosis factor are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998; 83: 859-862
16. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111-2119
17. Kunkel SL, Spengler M, May MA, Spengler R, Larrick J, Remick D. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. J Biol Chem 1988; 263: 5380-5384
18. Langeler EG, Fiers W, van Hinsbergh VW. Effects of tumor necrosis factor on prostacyclin production and the barrier function of human endothelial cell monolayers. Arteriosclerosis & Thrombosis 1991; 11: 872-881
19. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Annl NY Acad Sciences 1999; 892: 146-154
20. McCarty MF. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. Med Hypotheses 1999; 52: 465-477
21. Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, Kibata M. Relationship between serum tumor necrosis factor- and insulin resistance in obese men with Type 2 diabetes mellitus. Diabetes Res Clin Prac 2001; 52: 119-123
22. Nishimura S, Satoh J, Toyota T. Serum TNF α levels and diabetic complications in NIDDM patients. Diabetologia 1997; 40 (Suppl 1): A601
23. Norman JG, Fink GW, Franz MG. Acute pancreatitis induces intrapancreatic tumor necrosis factor gene expression. Arch Surgery 1995; 130: 966-970
24. Ollivier V, Parry GC, Cobb RR, deProst D, Mackman N. Elevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocyclic cells and endothelial cells. J Biol Chem 1996; 271: 20828-20835
25. Qiang X, Satoh J, Sagara M, Fukuzawa M, Masuda T, Miyaguchi S, Takahashi K, Toyota T. Gliclazide inhibits diabetic neuropathy irrespective of blood glucose levels in streptozotocin-induced diabetic rats. Metabolism 1998a; 47: 977-981
26. Qiang X, Satoh J, Sagara M, Fukuzawa M, Masuda T, Sakata Y, Muto G, Muto Y, Takahashi K, Toyota T. Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetologia 1998 b; 41: 1321-1326
27. Sagara M, Satoh J, Wada R, Yagihashi S, Takahashi K, Fukuzawa M, Muto G, Muto Y, Toyota T. Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine. Diabetologia 1996; 39: 263-269
28. Sagara M, Satoh J, Zhu XP, Takahashi K, Fukuzawa M, Muto G, Muto Y, Toyota T. Inhibition with N-acetylcysteine of enhanced production of tumor necrosis factor in streptozotocin-induced diabetic rats. Clin Immunol Immunopathol 1994; 71: 333-337
29. Satoh J, Seino H, Abo T, Tanaka S, Shintani S, Ohta S, Tamura K, Sawai T, Nobunaga T, Oteki T. Recombinant human tumor necrosis factor alpha suppresses autoimmune diabetes in nonobese diabetic mice. J Clin Invest 1989; 84: 1345-1348
30. Shteinberg D, Halak M, Shapiro S, Kinarty A, Sobol E, Lahat N, Karmeli R. Adbominal aortic aneurys and aortic occlusive disease: a comparison of risk factors and inflammatory response. Euro J Vasc Endocasc Surg 2000; 20: 462-465
31. Stephens JM, Pekala PH. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J Biol Chem 1991; 266: 21839-21845
32. Sushil KJ, Krishnaswamy K, Gideon L, Robert M, Joseph AB Jr. Hyperketonemia increases tumor necrosis factor-α secretion in cultured U937 monocytes and type 1 diabetic patients and is apparently mediated by oxidative stress and cAMP deficiency. Diabetes 2002; 51: 2287-2293
33. Tanaka S, Seino H, Satoh J, Fujii N, Rikiishi H, Zhu XP, Takahashi K, Sagara M, Nobunaga T, Toyota T. Increased in vivo production of tumor necrosis factor after development of diabetes in nontreated, long-term diabetic BB rats. Clin Immunol Immunopathol 1992; 62: 258-263
34. Yang XD, Tisch R, Singer SM, Cao ZA, Liblau RS, Schreiber RD, McDevitt HO. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 1994; 180: 995-1004
35. Yokoyama H, Deckert T. Central role of TGF-β in the pathogenesis of diabetic nephropathy and macrovascular complications: a hypothesis. Diabetic Med 1996; 13: 313-320
36. Yuuki T, Kanda T, Kimura Y, Kotajima N, Tamura J, Kobayashi I, Kshi S. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Comp 2001; 15: 257-259